CLAIMS

1. A therapeutic agent for diabetic ischemic disease, which comprises hepatocyte growth factor (HGF) as the effective ingredient.

5   2. The therapeutic agent according to claim 1, used for administration to the ischemic site.

3. The therapeutic agent according to claim 1 or 2, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic

10   ischemic myocardial infarction.

4. The therapeutic agent according to claim 3, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

5. The therapeutic agent according to any of claims 1 to 4, used for administration into the muscle of the ischemic site.

15   6. The therapeutic agent according to any of claims 1 to 5, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

7. The therapeutic agent according to any of claims 1 to 6, which is to be administered repeatedly as needed.

8. The therapeutic agent according to any of claims 1 to 7, wherein

20   the amount of HGF gene used is at least 50 μg.

9. A method for the treatment of diabetic ischemic disease, which comprises the transfer of the HGF gene into human.

10. The method according to claim 9, wherein the HGF gene is administered to an ischemic site.

25   11. The method according to claim 9 or 10, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction.

12. The method according to claim 11, wherein the diabetic ischemic

30   disease is diabetic lower limb ischemic disease.

13. The method according to any of claims 9 to 12, wherein the HGF gene is administered into the muscle of ischemic site.

14. The method according to any of claims 9 to 13, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

35   15. The method according to any of claims 9 to 14, wherein the HGF gene is administered repeatedly as needed.

16. The method according to any of claims 9 to 15, wherein the amount of HGF gene to be administered is at least 50 μg.

17. Use of the HGF gene for preparing therapeutic agents for diabetic ischemic disease.

18. The use according to claim 17, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy or diabetic ischemic myocardial infarction.

19. The use according to claim 18, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.

20. The use according to any of claims 17 to 19, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

21. The use according to any of claims 17 to 20, wherein the amount of HGF gene to be used is at least 50 μg.